Recent insights into HIV accessory proteins

Current Infectious Disease Reports

Volumn 5, Issue 5, 2003, Pages 439-450

  Anderson, Jenny L ^b   Hope, Thomas J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; NEF PROTEIN; VIF PROTEIN; VIRUS PROTEIN;

DRUG TARGETING; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 2442681004     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0024-8     Document Type: Review

References (99)

1. Hahn Bh, Shaw GM, De Cock KM, Sharp PM: AIDS as a zoonosis: scientific and public health implications. Science 2000, 287:607-614.
2. Strebel K, Daugherty D, Clouse K, et al.: The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 1987, 328:728-730.
3. Lake J, Carr J, Feng F, et al.: The role of Vif during HIV-1 infection: interaction with novel host cellular factors. J Clin Virol 2003, 26:143-152.
4. Simon JH, Miller DL, Fouchier RA, Malim MH: Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function. Virology 1998, 248:182-187.
5. Kao S, Akari H, Khan MA et al.: Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol 2003, 77:1131-1140.
6. Bour S, Strebel K: HIV accessory proteins: multifunctional components of a complex system. Adv Pharmacol 2000, 48:75-119.
7. von Schwedler U, Song J, Aiken, Trono D: Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993, 67:4945-4955.
8. Goncalves L, Silva F, Freitas-Vieira A, et al.: Function neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse trancscription and viral replication. J Biol Chem 2002, 277:32036-32045.
9. Madani N, Millete R, Platt EJ, et al.: Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J Virol 2002, 76:11133-11138.
10. Li L, Olvera JM, Yoder KE, et al.: Role of the non-homologous DNA end joining pathaway in the early steps of retroviral infection. EMBO J 2001, 20:3272-3281.
11. Hoglund S, Ohagen A, Lawrence K, Gabuzda D: Role of vif during packing of the core of HIV-1. Virology 1994, 201:349-355.
12. Khan MA, Akari H, Kao S, et al.: Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol 2002, 76:9112-9123.
13. Madani N, Kabat D: An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol 1998, 10251-10255.
14. Simon JH, Gaddis NC, Fouchier RA, Malim MH: Evidence for a newly discoverd cellular anti-HIV-1 phenotype. Nat Med 1998, 4:1397-1400.
15. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
16. Zhang H, Pomerantz R, Dornadula G, Sun Y: Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol 2000, 74:8252-8261.
17. Bourara K, Litvak S, Araya A: Generation of G-to-A and C-to-U changes in HIV-1 transcripts by RNA editing. Science 2000, 289:1564-1566.
18. Berkhout B, Das AT, Beerens N: HIV-1 RNA editing, hypermutation, and error-prone reverse transcription. Science 2001, 292;7.
19. Hassaïne G, Courcoul M, Bessou G, et al.: The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral Vif protein. J Biol Chem 2001, 276:16885-16893.
20. Zimmerman C, Klein KC, Kiser PK, et al.: Identication of a host protein essential for assembly of immature HIV-1 capsids. Nature 2002, 415:88-92.
21. Martinand C, Montavon C, Salehzada T, et al.: RNase L inhibitors is induced during human immunodeficiency virus type 1 infection and down regulates the 2-5A/RNase L pathway in human T cells. J Virol 1999, 73:290-296.
22. Sharp PM, Bailes E, Stevenson M, et al.: Gene acquisition in HIV and SIV. Nature 1996, 383:586-587.
23. Fletcher TM 3rd, Brichacek B, Sharova N, et al.: Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J 1996, 15:6155-6165.
24. Heinzinger NK, Bukrinsky MI, Haggerty SA, et al.: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994, 91:7311-7315.
25. Sherman MP, Schubert U, Williams SA, et al.: HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology 2002, 302:95-105.
26. Sherman MP, De Noronha CM, Williams SA, Greene WC: Insights into the biology of HIV-1 viral protein R. DNA Cell Biol 2002, 21:679-688.
27. Elder RT, Benko Z, Zhao Y: HIV-1 VPR modulates cell cycle G2/M transition through an alternative cellular mechanism other than the classic mitotic checkpoints. Front Biosci 2002, 7:d349-d357.
28. Chowdhury IH, Wang XF, Landau NR, et al.: HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest. Virology 2003, 305:371-377.
29. de Noronha CM, Sherman MP, Lin HW, et al.: Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 2001, 294:1105-1108.
30. Goh WC, Rogel ME, Kinsey CM, et al.: HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nature Med 1998, 4:65-71.
31. Sawaya BE, Khalili K, Gordon J, et al.: Cooperation interation between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem 2000, 275:35209-35214.
32. Mouland AJ, Coady M, Yao XJ, Cohen EA: Hypophosphorylation of poly(A) polymerase and increased polyadenylation activity are associated with human immunodeficiency virus type 1 Vpr expression. Virology 2002, 292:321-330.
33. Brasey A, Lopez-Lastra M, Ohlmann T, et al.: The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol 2003, 77:3939-3949.
34. Sachs AB: Cell cycle-dependent translation initiation: IRES elements prevail. Cell 2000, 101:243-245.
35. Gale M, Tan SL, Katze MG: Translational control of viral gene expression in eukaryotes. Microbiol Mol Biol Rev 2000, 64:239-280.
36. Buck CB, Shen X, Egan MA, et al.: The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site. J Virol 2001, 75:181-191.
37. Zhu Y, Roshal M, Li F, et al.: Upregulation of survivin by HIV-1 Vpr. Apoptosis 2003, 8:71-79.
38. Stewart SA, Poon B, Jowett JB, Chen IS: Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 1997, 71:5579-5592.
39. Kino T, Gragerov A, Slobodskaya O, et al.: Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 2002, 76:9724-9734.
40. Sherman MP, Greene WC: Slipping thorough the door: HIV entry into the nucleus. Microbes Inject 2002, 4:67-73.
41. Vasu SK, Forbes DJ: Nuclear pores and nuclear assembly. Curr Opin Cell Biol 2001, 13:363-375.
42. Sherman MP, de Noronha CM, Heusch MI, et al.: Nucleocytoplasmic shutting by human immunodeficiency virus type 1 Vpr. J Virol 2001, 75:1522-1532.
43. Le Rouzic E, Mousnier A, Rustum C, et al.: Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1. J Biol Chem 2002, 277:45091-45098.
44. McDonald D, Vodicka MA, Lucero G, et al.: Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 2002, 159:441-452.
45. Whittaker GR, Kann M, Helenius A: Viral entry into the nucleus. Annu Rev Cell Dev Biol 2000, 16:627-651.
46. Dvorin JD, Bell P, Maul GG, et al.: Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J Virol 2002, 76:12087-12096.
47. van de Bovenhamp M, Nottet HS, Pereira CF: Interactions of human immunodeficiency virus-1 proteins with neurons: possible role in the development of human immunodeficiency virus-1 associated dementia. Eur J Clin Invest 2002, 32:619-627.
48. Muthumani K, Hwang DS, Desai BM, et al.: HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 2002, 277:37820-37831.
49. Jacotot E, Ravagnan L, Loeffler M, et al.: The HIV-1 viral protein R induces apoptosis via a derect affect on the mitochondrial permeability transition pore. J Exp Med 2000, 191:33-46.
50. Yuan H, Xie YM, Chen IS: Depletion of Wee-1 kinase is necessary for both human immunodeficiency virus type 1 Vpr-and gamma irradiation-induced apoptosis. J Virol 2003, 77:2063-2070.
51. Somasundaran M, Sharkey M, Brichacek B, et al.: Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci USA 2002, 99:9503-9508.
52. Strebel K, Klimkait T, Martin M: A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 1988, 241:1221-1223.
53. Deora A, Ratner L: Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation. J Virol 2001, 75:6714-6718.
54. Marassi FM, Ma C, Gratkowski H, et al.: Correlation of the structural and functional domains in the membrane protein Vpu from HIV-1. Proc Natl Acad Sci USA 1999, 96:14336-14341.
55. Bour S, Boulerice F, Wainberg MA: Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1. J Virol 1991, 65:6387-6396.
56. Margottin F, Bour S, Durand H, et al.: A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998, 1:565-574.
57. Bour S, Perrin C, Akari H, Strebel K: The human immunodeficiency virus type 1 Vpu protein inhibits NF-kB activation by interfering with bTrCP-mediated degradation of IkBb. J Biol Chem 2001, 276:15920-15928.
58. Casella Cr, Rapaport EL, Finkel TH: Vpu increase susceptibility of human immunodeficiency virus type 1-infected cells to Fas killing. J Virol 199, 73:92-100.
59. Akari II, Bour S, Kao S, et al.: The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by supressing the nuclear factor kappB-dependent expression of antiapoptotic factors. J Exp Med 2001, 194:1299-1311.
60. Callahan MA, Handley MA, Lee Y-H, et al.: Functional interaction of human immunodeficiency virus type 1 Vpu and Gag with a novel member of the tetratricopeptide repeat protein family. J Virol 1998, 72:5189-5197.
61. Handley MA, Paddock S, Dall A, Panganiban AT: Association of Vpu-binding protein with microtubles and Vpu-dependent redistribution of HIV-1 Gag protein. Virology 2001, 291:198-207.
62. Bour S, Perrin C, Strebel K: Cell surface CD4 inhibits HIV-1 particle release by interfering with Vpu activity. J Biol Chem 1999, 274:33800-33806.
63. Deacon NJ, Tsykin A, Solomon A, et al.: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991.
64. Kirchhoff F, Greenough TC, Brettler DB, et al.: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995, 332:228-232.
65. Greenway AL, Holloway G, McPhee DA: HIV-1 Nef: a critical factor in viral-induced pathogenesis. Adv Pharmacol 2000, 48:299-343.
66. Forshey BM, Aiken C: Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of nef with the subviral ribonucleoprotein complex. J Virol 2003, 77:4409-4414.
67. Ahmad N, Venkatesan S: Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science 1988, 241:1481-1485.
68. Cullen BR: HIV-1 auxiliary proteins: making connections in a dying cell. Cell 1998, 93:685-692.
69. Janvier K, Craig H, Hitchin D, et al.: HIV-1 Nef stabilizes the association of adaptor protein complexes with membranes. J Biol Chem 2003, 278:8725-8732.
70. Arora VK, Fredericksen BL, Garcia JV: Nef: agent of cell subversion. Microbes Infect 2002, 4:189-199.
71. Geyer M, Yu H, Mandic R, et al.: Subunit H of the V-ATPase binds to the medium chain of adaptor protein complex 2 and connects Nef to the endocytic machinery. J Biol Chem 2002, 277:28521-28529.
72. Lundquist CA, Tobiume M, Zhou J, et al.: Nef-mediated down-regulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol 2002, 76:4625-4633.
73. Stoddart CA, Geleziunas R, Ferrell S, et al.: Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis. J Virol 2003, 77:2124-2133.
74. Blagoveshchenskaya AD, Thomas L, Feliciangeli SF, et al.: HIV-1 Nef downregulates MHC-1 by a PACS-1 and P13K-regulated ARF6 endocytic pathway. Cell 2002, 111:853-866.
75. Kasper MR, Collins KL: Nef-mediated disruption of HLA-A2 trasport to the cell surface in T cells. J Virol 2003, 77:3041-3049.
76. Williams M, Roeth JF, Kasper MR, et al.: Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking. J Virol 2002, 76:12173-12184.
77. Tomiyama H, Akari H, Adachi A, Takiguchi M: Different effects of Nef-mediated HLA class I down-regulation on human immunodeficiency virus type 1-specific CD8(+) T-cell cytolytic activity and cytokine production. J Virol 2002, 76:7535-7543.
78. Yang OO, Nyuyen PT, Kalams SA, et al.: Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J Virol 2002, 76:1626-1631.
79. Sol-Foulon N, Moris A, Nobile C, et al.: HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 2002, 16:145-155.
80. Renkema GH, Saksela K: Interactions of HIV-1 NEF with cellular signal transducing proteins. Front Biosci 2000, 5:D268-D283.
81. Choe EY, Schoenberger ES, Groopman JE, Park IW: HIV Nef inhibits T cell migration. J Biol Chem 2002, 277:46079-46084.
82. Packler OT, Baur AS: Live and let die: Nef functions beyond HIV replication. Immunity 2002, 16:493-497.
83. Baur AS, Sawai ET, Dazin P, et al.: HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity 1994, 1:373-384.
84. Liu X, Schrager JA, Lange GD, Marsh JW: HIV Nef-mediated cellular phenotypes are differentially expressed as a function of intracellular Nef concentrations. J Biol Chem 2001. 276:32763-32770.
85. Schrager JA, Der Minassian V, Marsh JW: HIV Nef increases T cell ERK MAP kinase activity. J Biol Chem 2002, 277:6137-6142.
86. Greenway AL, McPhee DA, Allen K, et al.: Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J Virol 2002, 76:2692-2702.
87. Varin A, Manna SK, Quivy V, et al.: Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J Biol Chem 2003, 278:2219-2227.
88. Miller MD, Warmerdan MT, Page KA, et al.: Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J Virol 1995, 69:579-584.
89. Aiken C, Trono D: Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995, 69:5048-5056.
90. Chazal N, Singer G, Aiken C, et al.: Human immunodeficiency virus type 1 particles pseudotype with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol 2001, 75:4014-4018.
91. Dorfman T, Popova E, Pizzato M, Gottlinger HG: Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix. J Virol 2002, 76:6857-6862.
92. Papkalla A, Munch J, Otto C, Kirchhoff F: Nef enchances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism. J Virol 2002, 76:8455-8459.
93. Zhou J, Aiken C: Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope. J Virol 2001, 75:5851-5859.
94. Goldsmith MA, Warmerdam MT, Atchison RE, et al.: Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J Virol 1995, 69:4112-4121.
95. Saksela K, Cheng G, Baltimore D: Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth to Nef+ viruses but nto for down-regulation of CD4. EMBO J 1995, 14:484-491.
96. Kestler HW 3rd, Ringler DJ, Mori K, et al.: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65:651-662.
97. Chakrabarti LA, metzner KJ, Ivanovic T, et al.: A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication. J Virol 2003, 77:1245-1256.
98. Birch MR, Learmont JC, Dyer WB, et al.: An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J Clin Virol 2001, 22:263-270.
99. Goff SP: Death by deamination: a novel host restriction system for HIV-1. Cell 2003 114:281-283.